Lynas share price: what to watch after a late-Friday filing before ASX trade resumes
25 January 2026
1 min read

Lynas share price: what to watch after a late-Friday filing before ASX trade resumes

Sydney, Jan 25, 2026, 17:23 AEDT — Market closed

  • After Friday’s close, Lynas will pause trading for an extended break as the ASX remains closed Monday in observance of Australia Day
  • A late Friday filing revealed a shift in a major stake in the rare earths producer
  • After a sharp move this month, investors are zeroing in on production stability and rare-earth prices

Lynas Rare Earths Ltd shares (ASX:LYC) closed Friday at A$16.86, marking a 0.66% gain following a choppy session that saw prices fluctuate between A$17.79 and A$16.77. 1

Timing is key. Australia’s primary exchange shuts Monday for Australia Day, extending the pause until the next session. Investors will have extra time to digest filings and sector updates ahead of trading. 2

Late Friday, an exchange notice revealed a “change in substantial holding” for Lynas filed after the market closed. In Australia, a “substantial holder” typically means an investor owning 5% or more of a company’s shares, and any changes must be reported. 3

The filing follows Lynas’ December-quarter update earlier this week, which highlighted a mixed picture: better sales and pricing, but some operational setbacks. The company reported quarterly gross sales revenue of A$201.9 million and total rare earth oxide (REO) output at 2,382 tonnes, including 1,404 tonnes of NdPr (neodymium-praseodymium, a key magnet material for EVs and wind turbines). Lynas closed the quarter with A$1.03 billion in cash and short-term deposits. It also revealed plans to explore off-grid power solutions after disruptions at its Kalgoorlie plant impacted production. 4

Lynas’s recent surge offers a snapshot of investor sentiment on non-China supply. It also raises the question: do tougher operating conditions push prices up, or simply drive costs higher?

Management turnover remains a quiet concern. CEO and managing director Amanda Lacaze is set to retire at the end of the financial year, the company confirmed, with the board already conducting a search for her replacement. 5

Sell-side opinions remain mixed. According to TipRanks data from Friday, Bell Potter stuck with a “sell” rating but nudged its price target up to A$11.15 — still about 34% under Friday’s closing price. 6

The debate heats up around that gap. Bulls point to the strategic angle and potential upside if NdPr pricing surprises on the high side. Bears, however, repeatedly flag execution risks and fret over what could unfold if prices slip even slightly.

The downside is clear-cut: additional power outages in Western Australia, a sluggish rebound at the Malaysian facility post-maintenance, or hold-ups in growth projects could drag volumes down and push the market toward a steeper cost structure.

The market was closed Monday, so all eyes turn to Tuesday’s reopening. Investors will be watching closely to see if the late-Friday holding notice signals normal register shifts or if big players are making significant moves in or out of Lynas at these prices.

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

Amazon stock tumbles on $200 billion AI spend plan — what to know before Monday

7 February 2026
Amazon shares fell 5.6% to $210.32 on Friday after the company projected about $200 billion in 2026 capital expenditures, triggering investor concern over AI spending. The stock had already dropped 11.5% after-hours Thursday. Amazon forecast Q1 net sales of $173.5–$178.5 billion and operating income of $16.5–$21.5 billion. Analyst Gil Luria downgraded Amazon, citing rising investment as its cloud lead narrows.
ANZ share price heads into Australia Day shutdown as CPI and NZ court case come into focus
Previous Story

ANZ share price heads into Australia Day shutdown as CPI and NZ court case come into focus

Telstra share price holds at A$4.72: what ASX investors are watching before results and the next dividend
Next Story

Telstra share price holds at A$4.72: what ASX investors are watching before results and the next dividend

Go toTop